HIMS Hims & Hers Health, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
13:51
Sep 01
Sep 01
Tokenized HIMS weekend float squeeze noted, no view
Author greets HIMS shareholders on a day when tokenized HIMS traded at a 37% premium to the NYSE close due to a weekend float squeeze on Robinhood Chain, no directional commitment stated.
LOW
21:24
Aug 31
Aug 31
The author agrees with the platform thesis but frames it as a difficult execution challenge.
The author agrees with the platform thesis but frames it as a difficult execution challenge, not a personal position or trade call.
LOW
20:04
Aug 31
Aug 31
Buy HIMS as Spotify-like healthcare distribution platform.
Buy HIMS as a platform building a healthcare membership flywheel, leveraging its subscriber base and data to become an essential distribution partner for pharma like Novo Nordisk.
MED
20:04
Aug 31
Aug 31
Hims undervalued as emerging healthcare platform
Buy $HIMS for long-term platform optionality: with millions of existing consumers and pharma/diagnostics innovators potentially choosing Hims as their distribution platform, the current telehealth valuation could re-rate materially if Dudum executes.
MED
19:41
Aug 31
Aug 31
5,000 US sailors land in Pattaya, and the author claims this will “tank the bluepill market” for HIMS this week. If traders treat the event as a negative catalyst for HIMS’s ED/telehealth demand, the stock/options could see short-term downside pressure toward the 27.5 strike. Author’s stated position is a 27.5 put on HIMS; it’s a short-term meme bet rather than a fundamentals-driven trade. Sailors get free military healthcare, so they may never have been HIMS customers anyway; the event is too small to move HIMS revenue; stock could rally on sex/STD-related pharma sentiment instead.
HIGH
14:26
Aug 26
Aug 26
Author hopes HIMS triples but clarifies their point was about growth rate valuation.
Author hopes HIMS triples but clarifies their point was about growth rate valuation, not a current position or trade call.
LOW
20:12
Aug 25
Aug 25
Visa's penalty and monitoring program add operational friction to Hims & Hers.
Visa's penalty and monitoring program add operational friction to Hims & Hers, but the author maintains a neutral HOLD rating balancing profitability concerns.
22:46
Aug 24
Aug 24
Visa complaint notice pressures Hims shares.
Hims & Hers was put on notice by Visa for excessive customer complaints in its weight-loss subscription business; the membership price jumps from $39 to $149 before drug costs, creating customer surprise and dispute risk, and shares dropped nearly 10%.
MED
20:22
Aug 24
Aug 24
Visa notice weighs on Hims & Hers.
Visa put Hims & Hers Health on notice over excessive customer complaints and credit card disputes tied to its weight-loss subscription pricing, where the introductory $39 membership jumps to $149 before drug costs; shares fell about 8%.
MED
20:55
Aug 21
Aug 21
Visa put Hims on notice over excessive customer complaints in its weight-loss subscription.
Visa put Hims on notice over excessive customer complaints in its weight-loss subscription business, adding to scrutiny of its billing and cancellation policies.
17:09
Aug 21
Aug 21
Stock starting to come back around
Notes the stock is starting to come back around, expressing broad basket momentum enthusiasm.
LOW
16:07
Aug 21
Aug 21
Strong CEO interview drives bullish momentum.
Highly bullish on HIMS following a strong CEO interview addressing the FTC lawsuit and outlining an AI healthcare vision, expecting the stock to stay above $30.
HIGH
16:44
Aug 20
Aug 20
Author highlights tickers on focus list
Author highlights these names on their focus list as showing strength and being under-owned.
LOW
15:09
Aug 20
Aug 20
Author recaps his 2025 call track record with a +57.85% return, notes recent drawdowns.
Author recaps his 2025 call track record with a +57.85% return, notes recent drawdowns, and says he is ready to add to positions and make new calls, implying continued bullishness on his winners.
18:44
Aug 19
Aug 19
The tweet simply notes HIMS is back to $30 with a chart link.
The tweet simply notes HIMS is back to $30 with a chart link, providing no directional view or position.
LOW
23:53
Aug 18
Aug 18
HIMS comeback driven by ecosystem/data moat
Expects HIMS to stage a strong comeback, endorsing the parent thesis that its healthcare ecosystem—AI, proprietary data, wearables, and cheaper GLP-1s—creates a durable competitive advantage.
MED
18:59
Aug 18
Aug 18
The tweet references Hims & Hers and its CEO Andrew Dudum with a back arrow emoji.
The tweet references Hims & Hers and its CEO Andrew Dudum with a back arrow emoji, but provides no explicit position or directional thesis.
LOW
17:19
Aug 18
Aug 18
HIMS AI-native data moat drives advantage
Hims & Hers is becoming an AI-native healthcare platform; by building its own AI on its closed-loop patient data across consultation, diagnosis, treatment and follow-up, it outperforms generic AI agentic vendors like Sierra and creates a durable data moat with lower operating costs.
HIGH
16:29
Aug 18
Aug 18
AI coach ecosystem boosts adherence and growth
Peptides are the next big growth area for Hims & Hers; the company acquired a Menlo Park peptide manufacturing plant and may be the only US company able to bring American-made peptides from raw ingredients to patients, with plans to launch if FDA moves peptides to category one and with clinical oversight plus home blood testing.
HIGH
20:02
Aug 17
Aug 17
Author counters a quoted list of sub-$30 stocks with four alternative tickers at similar price.
Author counters a quoted list of sub-$30 stocks with four alternative tickers at similar price levels, but provides no directional thesis or position disclosure, so these are watch items.
LOW
19:44
Aug 17
Aug 17
Questions HIMS bull case due to competition.
Questions the bull case for HIMS, noting high competition and multiple alternative sources for weight loss pills.
MED
11:28
Aug 15
Aug 15
The author lists a large basket of tickers without any explicit position language.
The author lists a large basket of tickers without any explicit position language or directional thesis, so all are indexed as watch.
LOW
17:38
Aug 14
Aug 14
Author reflects on past SPAC winners and names current potential picks but frames them.
Author reflects on past SPAC winners and names current potential picks but frames them as opportunities rather than explicit current positions or forward calls.
LOW
23:57
Aug 11
Aug 11
Hims & Hers delivered a monster quarter.
Hims & Hers just reported an absolute monster quarter that surprised even the research team with its strength.
HIGH
18:50
Aug 11
Aug 11
HIMS Eucalyptus deal fast-tracks global expansion
Buy HIMS as the Eucalyptus acquisition accelerates international expansion into Australia and Japan by years, delivering an existing 775,000-customer base, local regulatory infrastructure, and brand equity while eliminating a direct competitor — all faster and cheaper than organic entry.
MED
13:33
Aug 11
Aug 11
The author sarcastically notes that most people still misunderstand HIMS.
The author sarcastically notes that most people still misunderstand HIMS, implying an edge but without stating a position or forward call.
LOW
12:07
Aug 11
Aug 11
Premarket movers report shows Mag 7 stocks mixed while ACVA, BW, CAH, P, FRMI, PLUG, RPD.
Premarket movers report shows Mag 7 stocks mixed while ACVA, BW, CAH, P, FRMI, PLUG, RPD, and RIOT rise on earnings or deal news, with HIMS and ONON falling on weak forecasts.
11:32
Aug 11
Aug 11
US pre-market movers show mixed futures with notable individual stock reactions.
US pre-market movers show mixed futures with notable individual stock reactions including Intel's increased share sale, Getty's surprise loss, Riot's AI data center deal, and several earnings-driven moves across the board.
07:00
Aug 11
Aug 11
Buy HIMS under $40 after strong result
Buy HIMS below $40 on the back of a very good result; the strong outcome is the catalyst cited for the stated buy zone.
MED
04:36
Aug 11
Aug 11
Author shares detailed earnings reviews and portfolio access for HIMS, APP, SHOP.
Author shares detailed earnings reviews and portfolio access for HIMS, APP, SHOP, and SE but expresses no explicit directional position or trade call.
LOW
About HIMS Analyst Coverage
Buzzberg tracks HIMS (Hims & Hers Health, Inc.) across 58 sources. 327 bullish vs 36 bearish calls from 79 analysts. Sentiment: predominantly bullish (46%). 639 total trade ideas tracked. Past 7 days: 2 bullish, 1 bearish, 2 watch. Latest voices: caesarcapitalz, finnstockinger, moninvestor.